Zacks Research Has Bullish Forecast for PAHC Q2 Earnings

Key Points

• Zacks Research raised its Q2 2027 EPS forecast for Phibro Animal Health to $0.95 from $0.85 and projects FY2027, FY2028, and FY2029 earnings of $3.46, $3.65, and $3.87 per share, respectively.
• Phibro Animal Health recently exceeded quarterly expectations, reporting $0.85 EPS versus the $0.71 consensus and revenue of $396.75 million versus $381.18 million. The company provided FY2027 EPS guidance of $3.41–$3.59.
• Despite the improved earnings outlook, analysts maintain a broadly cautious stance, with one Buy rating and three Holds and a consensus price target of $47.67. The company also declared a quarterly dividend of $0.12 per share, representing a 1.4% annualized yield.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Equities researchers at Zacks Research lifted their Q2 2027 earnings estimates for Phibro Animal Health in a research report issued to clients and investors on Friday, September 18th. Zacks Research analyst Team now forecasts that the company will earn $0.95 per share for the quarter, up from their previous forecast of $0.85. The consensus estimate for Phibro Animal Health's current full-year earnings is $3.50 per share. Zacks Research also issued estimates for Phibro Animal Health's Q3 2027 earnings at $0.82 EPS, Q4 2027 earnings at $0.90 EPS, FY2027 earnings at $3.46 EPS, Q1 2028 earnings at $0.83 EPS, Q2 2028 earnings at $1.01 EPS, Q3 2028 earnings at $0.90 EPS, Q4 2028 earnings at $0.92 EPS, FY2028 earnings at $3.65 EPS and FY2029 earnings at $3.87 EPS.

Separately, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Phibro Animal Health in a research note on Friday, September 11th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Phibro Animal Health currently has an average rating of "Hold" and a consensus price target of $47.67.

Phibro Animal Health Stock Performance

PAHC stock opened at $34.56 on Monday. The firm has a market cap of $1.40 billion, a PE ratio of 14.16, a price-to-earnings-growth ratio of 1.00 and a beta of 0.46. The company has a current ratio of 2.96, a quick ratio of 1.27 and a debt-to-equity ratio of 1.84. The stock has a 50-day moving average price of $35.56 and a 200-day moving average price of $40.57. Phibro Animal Health has a 1-year low of $28.25 and a 1-year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, August 26th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.14. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. The business had revenue of $396.75 million for the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ranger Investment Management L.P. bought a new position in shares of Phibro Animal Health during the second quarter valued at about $9,182,000. Globeflex Capital L P bought a new stake in Phibro Animal Health in the 2nd quarter worth about $5,942,000. Allspring Global Investments Holdings LLC grew its position in Phibro Animal Health by 145.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company's stock worth $15,671,000 after purchasing an additional 169,628 shares in the last quarter. Castleark Management LLC purchased a new stake in Phibro Animal Health in the 1st quarter valued at about $7,904,000. Finally, Capricorn Fund Managers Ltd increased its stake in Phibro Animal Health by 45.1% in the 1st quarter. Capricorn Fund Managers Ltd now owns 267,045 shares of the company's stock valued at $14,770,000 after buying an additional 82,944 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a yield of 1.4%. Phibro Animal Health's dividend payout ratio is currently 19.67%.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $3.46 from $3.18, FY2028 EPS to $3.65 from $3.35, and issued a FY2029 forecast of $3.87. The firm also lifted estimates for several quarterly periods, including Q2 2027 to $0.95, Q3 2027 to $0.82, and Q4 2027 to $0.90.
• Positive Sentiment: The largest quarterly upgrades included Q2 2028 EPS to $1.01 from $0.91, Q3 2028 to $0.90 from $0.82, and Q4 2028 to $0.92 from $0.80. Q1 2028 was also raised slightly to $0.83 from $0.82.
• Neutral Sentiment: Zacks’ current-year consensus reference remains $3.51 EPS, while its FY2027 estimate of $3.46 is below that level but represents a substantial increase from its prior forecast. Investors may interpret the revisions as evidence of better longer-term earnings visibility rather than an immediate change to current-year results.

About Phibro Animal Health

Phibro Animal Health Corporation is a global animal-health and nutrition company that develops, manufactures and markets products intended to support the health, productivity and well-being of food-producing animals and companion animals. Its customers include livestock producers, veterinarians, feed manufacturers and distributors.

The company's product portfolio includes vaccines, medicated feed additives, nutritional specialties, mineral and vitamin premixes, feed additives and other products used in poultry, swine, cattle, aquaculture and companion-animal applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.